Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alligator CEO Discusses Pipeline Additions, Milestone Expectations And The IO Deal Landscape

Executive Summary

Alligator Bioscience’s Per Norlen discusses the latest addition to its pipeline, a first-in-class bispecific tumor-localized antibody targeting the checkpoint inhibitor CTLA-4.

Advertisement

Related Content

Deal Watch: Boehringer Teams Up In CNS Disorders Again, This Time With Domain
Alligator CEO Provides Snapshot Of Tumor-Directed IO Pipeline
J&J, Alligator strike immuno-oncology MAb deal worth up to $700m

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124243

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel